Fondo de Investigacion Sanitaria   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Madrid Spain (1980)

Organization Overview

First Clinical Trial
2002
NCT00622570
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Fondo de Investigacion Sanitaria | Fondo de Investigación Sanitaria (FIS)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Cardiac Output, Low (Phase 2)

Choroidal Neovascularization (Phase 3)

Fibrosis (Phase 3)

HIV Infections (Phase 3)

Hypertension (Phase 3)

Infarction (Phase 4)

Infections (Phase 3)

Intervertebral Disc Displacement (Phase 2)

Intracranial Hypertension (Phase 3)

Liver Cirrhosis (Phase 3)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Myocardial Infarction (Phase 4)

Myopia (Phase 3)

Neovascularization, Pathologic (Phase 3)

Peritonitis (Phase 3)

Pneumonia (Phase 4)

Pneumonia, Pneumococcal (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Ventricular Remodeling (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 22